콘텐츠로 건너뛰기
Merck
  • Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels.

Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels.

Biophysical journal (2013-02-28)
Michela De Bellis, Annamaria De Luca, Jean F Desaphy, Roberta Carbonara, Judith A Heiny, Ann Kennedy, Alessia Carocci, Maria M Cavalluzzi, Giovanni Lentini, Carlo Franchini, Diana Conte Camerino
초록

Previously identified potent and/or use-dependent mexiletine (Mex) analogs were used as template for the rational design of new Na(v)-channel blockers. The effects of the novel analogs were tested on sodium currents of native myofibers. Data and molecular modeling show that increasing basicity and optimal alkyl chain length enhance use-dependent block. This was demonstrated by replacing the amino group with a more basic guanidine one while maintaining a proper distance between positive charge and aromatic ring (Me13) or with homologs having the chirality center nearby the amino group or the aromatic ring. Accordingly, a phenyl group on the asymmetric center in the homologated alkyl chain (Me12), leads to a further increase of use-dependent behavior versus the phenyl Mex derivative Me4. A fluorine atom in paraposition and one ortho-methyl group on the xylyloxy ring (Me15) increase potency and stereoselectivity versus Me4. Charge delocalization and greater flexibility of Me15 may increase its affinity for Tyr residues influencing steric drug interaction with the primary Phe residue of the binding site. Me12 and Me15 show limited selectivity against Na(v)-isoforms, possibly due to the highly conserved binding site on Na(v). To our knowledge, the new compounds are the most potent Mex-like Na(v) blockers obtained to date and deserve further investigation.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Mexiletine hydrochloride, powder